# Asfotase Alfa (Strensiq)

Source: https://ourhealthnetwork.com/drugs/asfotase-alfa
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Asfotase Alfa?

Asfotase Alfa (brand name: Strensiq) is a tissue-nonspecific alkaline phosphatase.

## Brand names

Strensiq

## Indications

STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). STRENSIQ is a tissue nonspecific alkaline phosphatase indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).

## Conditions treated

- [Hypophosphatasia](https://ourhealthnetwork.com/conditions/hypophosphatasia)

## Mechanism of action

HPP is caused by a deficiency in TNSALP enzyme activity, which leads to elevations in several TNSALP substrates, including inorganic pyrophosphate (PPi). TNSALP is a metallo-enzyme that catalyzes the hydrolysis of phosphomonoesters with release of inorganic phosphate and alcohol.

## Drug classification

- Established Pharmacologic Class: Tissue-nonspecific Alkaline Phosphatase [EPC]
- Route of administration: SUBCUTANEOUS

## Common side effects

and hypersensitivity reactions, ectopic calcifications, injection site reactions, lipodystrophy

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)